Daily BriefsECM

Daily Brief ECM: Poor Performance Before UK Lawmakers Is SHEIN’s Latest Stumble on Journey To London (Or HK?) IPO and more

In today’s briefing:

  • Poor Performance Before UK Lawmakers Is SHEIN’s Latest Stumble on Journey To London (Or HK?) IPO
  • ECM Weekly (13th Jan 2025) – LG CNS, Bloks, Guming, Crizac, Shift Up, Adani, Wuxi
  • HUTCHMED to Divest 45% Stake in Non-Core Joint Venture with Shanghai Pharma


Poor Performance Before UK Lawmakers Is SHEIN’s Latest Stumble on Journey To London (Or HK?) IPO

By Daniel Hellberg

  • SHEIN’s general counsel frustrated UK lawmakers by refusing to answer certain questions
  • It’s the latest in a series of potential obstacles that could derail a planned London IPO
  • Add growing concerns over cotton supply chain & new threat from Amazon to existing risks

ECM Weekly (13th Jan 2025) – LG CNS, Bloks, Guming, Crizac, Shift Up, Adani, Wuxi

By Sumeet Singh


HUTCHMED to Divest 45% Stake in Non-Core Joint Venture with Shanghai Pharma

By Xinyao (Criss) Wang

  • HUTCHMED announced the disposal of 45% equity interest in SHPL for US$608 million, including selling 35% equity interest to GP Health Service Capital and 10% equity interest to Shanghai Pharma.
  • There’re synergies between SHPL and Shanghai Pharma regarding TCM business. It’s necessary for HUTCHMED to sell non-core JV to reserve cash flow in advance to focus on innovative drug business.
  • The entire valuation of SHPL reaches RMB10 billion, or about 15x P/E. If HUTCHMED’s innovative drug business can bear fruit, its valuation has more room to grow in the future.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars